Chugai Building On Roche Alliance Success As It Eyes Future: CEO Okuda
Digital Strategy Now In Focus
Executive Summary
In an exclusive interview with Scrip, Chugai's CEO says the now 20-year-old strategic partnership with Roche has been one of the keys to Chugai’s successful growth and has allowed smooth market expansion for both firms, as well as enabling R&D investment by the Japanese firm. A flexible, platform-based approach to R&D, rather than focusing on specific target diseases or technologies, has also benefitted Chugai, Osamu Okuda noted.
You may also be interested in...
Crovalimab Filed In Japan As More Phase III Results Released At EHA
The Chugai/Roche antibody has been filed for PNH in Japan as more details of its Phase III results are released.
Japan Q3 Roundup: Forex Impacts Majors Amid New Product Growth Expectations
Amid ongoing impact from exchange rates, Japan's five largest pharma firms showed mostly positive growth in the fiscal nine-month period. Enhertu will continue to drive Daiichi Sankyo, while Shionogi is forecasting record-breaking revenue on oral COVID-19 drug Xocova and Eisai is rolling out closely-watched Alzheimer's contender Leqembi.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: the best of J.P. Morgan; Novartis on its US-first commercial plan; Chugai CEO talks to Scrip on the Roche alliance and more; Scrip Asks what this year holds for pricing and reimbursement; and the global outlook for biopharma funding.